The Role of Induction (Neoadjuvant) Chemotherapy in Stage IIIA NSCLC

¹ From the Medical Oncology Service, the Molecular Biology Laboratory of Cancer, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
² From the Medical Oncology Service, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
³ From the Molecular Biology Laboratory of Cancer, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
⁴ From the Thoracic Service, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
⁵ From the Radiation Oncology Service, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
⁶ From the Pneumology Service, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

Induction (neoadjuvant) chemotherapy has become an accepted treatment for stage IIIA (T1-3N2M0) non-small cell lung cancer. In two recent randomized trials, neoadjuvant chemotherapy plus surgery gave an increase in median survival at least fivefold greater than surgery alone. The Spanish Lung Cancer Group trial of preoperative chemotherapy, in which the cisplatin dose was randomized to either 50 mg/m² or 100 mg/m² plus 3 g/m² ifosfamide and 6 mg/m² mitomycin, examines the effect of K-ras gene mutations on tumor response and survival. Patients whose tumors contain K-ras gene mutations are more likely to develop distant metastases and have lower median survival than patients without such mutations. Microsatellite instability seems to be a frequent mechanism of genetic aberrations. Knowledge about these genetic alterations could have prognostic importance and may identify the patients who should receive the most aggressive additional treatment.